

# How May Proton Pump Inhibitors Impair Cardiovascular Health?

Roman A. Sukhovshin<sup>1</sup> · John P. Cooke<sup>1</sup>

Published online: 27 January 2016  
© Springer International Publishing Switzerland 2016

**Abstract** Proton pump inhibitors (PPIs) are among the most widely used drugs worldwide. They are used to treat a number of gastroesophageal disorders and are usually prescribed as a long-term medication or even taken without a prescription. There are a number of clinical studies that associate PPI use with an increased cardiovascular risk. In this article, we review the clinical evidence for adverse cardiovascular effects of PPIs, and we discuss possible biological mechanisms by which PPIs can impair cardiovascular health.

## Key Points

According to a majority of experimental and clinical observations, proton pump inhibitors (PPIs) appear to have adverse cardiovascular effects.

PPIs may affect cardiovascular health by several mechanisms, which include reduction of nitric oxide bioavailability, electrolyte imbalance and interaction with some antiplatelet agents.

Long-term administration of PPIs is not approved by the FDA and should be avoided, especially in patients at high cardiovascular risk.

## 1 Introduction

Proton pump inhibitors (PPIs) are among the most widely used drugs worldwide, with about US\$13 billion in annual sales [1, 2]. They are the standard treatment for acid-related disorders, such as peptic ulcer disease, gastroesophageal reflux disease, Zollinger–Ellison syndrome and idiopathic hypersecretion. PPIs are useful in the eradication of *Helicobacter Pylori* infection as well as for prevention of peptic ulcers and upper gastrointestinal bleeding in patients taking nonsteroidal anti-inflammatory drugs (e.g., aspirin) or antiplatelet agents [3, 4].

PPIs are considered to be safe drugs when used as directed, and are now available over-the-counter. However, PPIs were approved by the FDA for short-term use (weeks, not months or years). It has become a common clinical practice to prescribe these agents for long-term use [5–7]. Because these agents are now over-the-counter medications in the USA, their use is often not monitored by a health care specialist. The long-term use of PPIs may be associated with significant side effects. Accumulating evidence raises concerns regarding their effects on cardiovascular health. The intent of this article is to provide a balanced review of available information on PPIs in relation to cardiovascular risks and to discuss possible biological mechanisms by which PPIs can impair cardiovascular health.

## 2 Proton Pump Inhibitors (PPIs): Mechanisms of Therapeutic and Adverse Effects

PPIs are substituted benzimidazoles with  $\sim pK_a$  4 (weak bases). In the highly acidic environment of the gastric parietal cells, they undergo protonation to form cationic

✉ John P. Cooke  
jpcooke@houstonmethodist.org

<sup>1</sup> Department of Cardiovascular Sciences, Houston Methodist Research Institute, 6670 Bertner Ave, Houston, TX 77030, USA

sulfenamides or sulfenic acids. These protonated forms of the PPIs bind to the gastric  $H^+/K^+$ -ATPases (proton pumps) [8]. The proton pumps exchange intracellular hydrogen ions for extracellular potassium ions. Proton pumps are integrated into the membranes of secretory canaliculi of the parietal cells, and export hydrogen ions into the ducts of the gastric glands where hydrogen ions combine with chloride ions, forming hydrochloric (gastric) acid [9]. By binding to the proton pumps, PPIs prevent  $H^+/K^+$  exchange within secretory canaliculi and suppress gastric acid secretion, independent of the nature of the secretory stimuli [3, 10].

Protonated (active) forms of PPIs are unstable and in the stomach will degrade before reaching their target. Accordingly, all PPIs are administered as uncharged prodrugs and formulated as either enteric-coated capsules or a powder for intravenous injections [11]. The enteric-coating protects PPIs until they reach the intestine, where they are absorbed and then circulate systemically. The neutral pH of the blood permits the PPIs to remain in the prodrug form while circulating and being distributed into the tissues. After reaching the parietal cells, the PPIs are released into the acidic environment of the secretory canaliculi, which are membrane invaginations of the outer surface of the parietal cell facing the stomach lumen. At that point, PPIs are activated by the low pH and form disulfides with cysteines of active proton pumps (primary with Cys813) [11, 12]. As a result, PPIs are thought to preferentially accumulate in the parietal cell, reaching about 1000-fold higher concentrations than in the blood [13]. Parenthetically, it should be noted that activation of the PPIs may occur to a certain extent in other cells, in particular, within the acidic environment of lysosomes [14, 15]. Therefore, it is possible that PPIs might also reduce the acidification of lysosomes. Even if this effect is modest, the possible effects of long-term PPI use on lysosomal acidification and proteostasis has not received sufficient attention.

The available PPIs include six FDA-approved drugs (in the order they were brought to the market): omeprazole, lansoprazole, rabeprazole, pantoprazole, esomeprazole and dexlansoprazole. In general, PPIs are rapidly metabolized by the liver via the cytochrome P-450 enzyme system, primarily via CYP2C19 and CYP3A4. Subsequently, PPI metabolites are excreted in the urine [16]. Based upon polymorphisms of the P-450 enzymes, patients can be classified as homozygous extensive metabolizers of PPIs (homoEMs), heterozygous extensive metabolizers (heteroEMs) and poor metabolizers [17, 18]. Pharmacokinetic properties of PPIs vary depending on the particular drug (reviewed elsewhere [3, 8, 19]). Briefly, the elimination half-lives of these drugs range between 0.5 and 2 h, with an

area under the curve (AUC) of plasma concentrations between 0.58 and 13.5  $\mu\text{mol}\cdot\text{h}/\text{L}$  and maximal plasma concentration ( $C_{\text{max}}$ ) between 0.23 and 23.2  $\mu\text{mol}/\text{L}$ . The target effect of PPIs is believed to depend on AUC rather than  $C_{\text{max}}$  [20].

Adverse effects reported to occur with PPIs include headache, diarrhea, constipation, nausea and rash, and occur in less than 5 % of people taking the drugs. These effects are similar amongst the class of PPIs and do not seem to be related to the duration of treatment [4, 8]. However, the duration of treatment may increase the risk of other adverse effects. Since gastric  $H^+/K^+$ -ATPases are inhibited by PPIs and gastric pH is increased, the release of gastrin from G cells is increased. Gastrin is a hormone that activates translocation of proton pumps from the vesicles to the membrane of secretory canaliculi. The PPI-induced hypergastrinemia can thereby cause rebound acid hypersecretion after withdrawal of PPIs, which occurs in 40 % of cases [21, 22]. In addition, hypergastrinemia may lead to gastric cell hyperplasia, formation of fundic gland polyps [23] (up to 10 % of cases if taken more than a year) or even gastric carcinoids in rare circumstances [24].

Suppression of gastric acid is known to reduce mineral calcium absorption; therefore, long-term PPI use is associated with osteoporosis and an increased risk of bone fractures [25, 26]. The incidence of enteric and systemic infections (such as *Clostridium difficile* colitis, nosocomial and community-acquired pneumonia) is noted to be higher in patients on PPIs and also can be explained by suppression of gastric acidity, which normally serves as one of the defense mechanisms against pathogens entering the digestive tract [27–29].

### 3 Accumulating Evidence of Adverse Cardiovascular Effects of PPIs

The possibility that PPIs may have an adverse effect on cardiovascular health was raised during randomized trials of novel antiplatelet agents. These effects were initially attributed to the fact that PPIs may impair the metabolic activation of certain anti-platelet agents, thereby increasing a risk of major adverse cardiac events (MACE). The interactions between PPIs and the antiplatelet agent clopidogrel have been extensively studied, because clopidogrel requires bioactivation by CYP2C19 and competes for this enzyme with some PPIs [30].

Multiple clinical trials assessing the benefit of clopidogrel in patients sustaining a myocardial infarction (MI) or undergoing a percutaneous coronary intervention revealed an increased incidence of MACE when these patients

received a PPI together with clopidogrel [31–33]. Concerned by possible PPI–clopidogrel interactions, the FDA issued a public health warning with a recommendation to avoid concomitant use of these drugs [34].

However, it soon became clear that the adverse effect of PPIs was not related to a metabolic interaction with clopidogrel. A nationwide retrospective cohort study (Denmark), which included 56,406 participants discharged after the first-time MI, reported a 30 % increase in the incidence of cardiovascular death, recurrent MI or stroke within the first month after discharge for those patients that were taking PPIs [35]. This adverse effect was independent of whether the patients were on clopidogrel.

Another population-based cohort study in Western Denmark tracked the use of clopidogrel and PPIs and the rate of MACE in 13,001 patients with coronary stent implantation during a 1-year follow-up period. Again, independent of the use of clopidogrel, PPIs as a class increased the risk of MACE by 25 % [36].

A case-control study performed among 23,655 patients hospitalized with acute MI reported an increased risk of recurrent MI in those participants taking PPIs. The increased risk was similar whether the patients were using clopidogrel [odds ratio (OR) 1.62, 95 % confidence interval (CI) 1.15–2.27] or not (OR 1.38, 95 % CI 1.18–1.61) [37].

A randomized clinical trial Clopidogrel for the Reduction of Events During Observation (CREDO), which included 21,116 participants undergoing, or with a high likelihood of undergoing, percutaneous coronary intervention and receiving clopidogrel with aspirin, also revealed an independent association between PPI use and cardiovascular events within a month and within a year after the intervention [hazard ratio (HR) 1.6, 95 % CI 1.08–2.5, and HR 1.5, 95 % CI 1.1–2.1, respectively] [38]. There was no additional risk registered in this trial when clopidogrel was administered together with PPIs.

A meta-analysis of 23 clinical studies evaluating PPI–clopidogrel interactions in patients with a high risk of MACE has been done recently. The authors also identified seven studies describing cardiovascular effects of PPIs in the absence of clopidogrel, and performed an analysis of these studies as well (107,423 patients in total) [39]. A significant cardiovascular risk was found with PPIs alone (OR 1.28, 95 % CI 1.14–1.44). In addition, this meta-analysis showed that PPIs reduced the benefit of clopidogrel, whether or not the specific PPI interfered with clopidogrel activation. For example, pantoprazole is metabolized mostly by CYP3A4 and should not significantly interfere with clopidogrel activation. Nevertheless, pantoprazole has a similar adverse effect on the clinical outcome as other PPIs, which suggests mechanisms

unrelated to clopidogrel bioactivation may account for the adverse effect of PPIs.

#### 4 Controversy Regarding the Adverse Effect of PPIs on Cardiovascular Health

After a drumbeat of studies suggesting that PPIs may increase MACE, two recent meta-analyses performed in cohorts of patients on dual antiplatelet therapy after MI called this warning into question. With respect to PPIs and adverse events, these meta-analyses papers focused on the conflicting results between observational studies and randomized trials: the former consistently reported higher event rates in patients receiving PPIs for various clinical outcomes; the latter showed no difference in outcomes compared to placebo. Melloni et al. analyzed 35 studies that were eligible for their analysis [40]. Only four of these were randomized controlled trials that assessed the effect of a PPI (omeprazole) when added to dual antiplatelet therapy; the other 31 were observational studies assessing the effect of PPIs compared with no PPIs. The observational studies consistently revealed an increased risk of MACE in patients using PPIs versus those not exposed to this class of drugs. By contrast, the randomized clinical trials showed no significant effect of omeprazole on ischemic events. The authors concluded that prospective studies of the effects of specific PPIs on MACE in patients on dual antiplatelet therapy were indicated. It is important to note that the randomized clinical trials studied a smaller number of patients (about one-tenth of the patients in the observational studies) and tended to be shorter in duration. In this regard, it is interesting to note that regardless of the design of the study, those with longer duration of follow-up tended to find an increased HR for those patients on PPIs.

Cardoso and co-workers performed a similar meta-analysis [41] and came to similar findings as Melloni and colleagues. They emphasize that the association between adverse outcomes and concomitant PPI–clopidogrel use persists in patients taking PPIs (rabeprazole or pantoprazole). Given that these medications are not expected to have a significant interaction with clopidogrel, they conclude that this finding further supports the hypothesis that use of a PPI is not the cause of increased adverse outcomes, but rather a marker of increased baseline risk. However, this reasoning is flawed if the PPIs have an adverse effect on cardiovascular health independent of clopidogrel activation.

Nevertheless, whether the association between PPIs and MACE is causal, or due to confounding factors, remains controversial. The potential source of confounding in observation studies associating PPIs with an MI risk may

be an increased use of acid-suppressing drugs in the period before hospitalization, because prodromal symptoms of MI are sometimes misinterpreted as dyspepsia [42]. Indeed, a case-crossover study among 3490 MI cases demonstrated that PPI prescription appeared to increase the risk of MI by 70 %. However, when the dispensation date of the PPI rather than prescription date was used to calculate the risk, this increase in the risk was diluted [43]. Inasmuch as there was a more prominent association of MI with PPI prescription than PPI usage, this study could be interpreted as indicating a lack of cause-and-relationship effects of PPIs on MI onset. Major limitations of this study included the small number of cases prescribed ( $n = 16$ ) or dispensed ( $n = 46$ ) PPIs in the “hazard period” 3 days before the MI. Indeed, the failure to find an association may be a type II statistical error, as the HR for those patients dispensed PPIs (1.29) was very similar to that of larger studies that found a significant association.

Another population-based study, which included 5550 hospital admissions for MI and 6003 admissions for heart failure, reported a risk for these adverse events with commencement of PPI therapy. However, it also revealed a risk of similar magnitude with other drugs exhibiting no known cardiac toxicity, such as H<sub>2</sub>-receptor antagonists and benzodiazepines [44]. These findings also suggest the possible presence of the confounding factors in observational studies associating PPI use with an increased cardiovascular risk. The major limitation of this study is its statistical design. Each patient’s follow-up was divided into three identical 4-week intervals. The first 4-week period followed the initiation of a PPI and was considered the primary risk interval, during which time admissions for acute MI or heart failure were taken to reflect an unintended consequence of drug therapy. The final 4-week interval was defined as the control interval; any event occurring during this interval was taken to render a causal association with drug therapy highly unlikely. Such a statistical design only makes biological sense if any adverse event of the drug has a fairly rapid onset. For drugs that cause an impairment in vascular homeostasis (see below), the adverse effect may take months or years to be manifested.

## 5 Risk of PPIs in the General Population

The previous studies primarily focused on the use of PPIs in patients at greater risk of MACE. Population-based studies aimed to explore the risk of new-onset MI in PPI users in the general population. The first one utilized propensity score-matching analysis as well as case-crossover analysis [45]. Propensity-score matching of over 250,000 individuals revealed a greater risk of MI within 4 months after PPI use (HR 1.58, 95 % CI 1.11–2.25).

These findings were re-confirmed by case-crossover analysis, in which 10,860 individuals were assessed. Of note, the case-crossover analysis also showed that H<sub>2</sub>-receptor antagonists, an alternative class of acid suppressing drugs, were not associated with an increased MI risk.

Recently, we performed a population-based study in a lower risk population utilizing a novel data-mining approach for pharmacovigilance. We queried over 16 million clinical documents on 2.9 million individuals from two unrelated clinical databases [46]. In each database, after propensity matching, PPI usage was associated with MI, independent of age and clopidogrel use (OR 1.16, 95 % CI 1.09–1.24), whereas H<sub>2</sub>-receptor antagonists lacked such an association. Furthermore, in a third database composed of a prospective cohort of patients undergoing elective coronary angiography, survival analysis revealed an increased risk of cardiovascular mortality among PPI users (HR 2.00, 95 % CI 1.07–3.78) during ~5 years of follow-up. This big data study, along with others, again raises concerns regarding an adverse effect of the PPIs on cardiovascular health.

## 6 Possible Mechanisms Underlying Cardiovascular Effects of PPIs

The evidence obtained in the aforementioned studies suggest that the underlying mechanism for cardiovascular effects of PPIs are not directly related to acid suppression, since H<sub>2</sub>-receptor antagonists are not associated with the cardiovascular risk [45, 46]. Furthermore, it seems unlikely that any adverse cardiovascular effects of PPIs are related to interference with clopidogrel metabolism, as PPIs that do not interfere with clopidogrel activation are also associated with increased cardiovascular events. Furthermore, antiplatelet agents that are not dependent upon bioactivation by CYP2C19 also seem to have less benefit when co-administered with PPIs [47, 48].

We have provided evidence that the adverse cardiovascular effects of PPIs may be mediated, at least in part, by their effect to reduce the activity of nitric oxide synthase (NOS). Endothelium-derived nitric oxide (NO) is critically involved in regulation of vascular homeostasis. NO causes vasodilation and reduces vascular cell proliferation, platelet adhesion and aggregation, and endothelial-leukocyte interactions [49–51]. In experimental animals, pharmacological or genetic activation of endothelial NOS attenuates atherosclerosis progression [52–54]. Accumulating evidence from epidemiological studies indicates that humans with impaired NOS activity are at greater risk of MACE [55–57].

A circulating inhibitor of NOS is elevated in patients with cardiovascular disease or risk factors. This NOS

inhibitor is known as asymmetric dimethylarginine (ADMA). Plasma ADMA competitively inhibits the NOS enzyme, and can also induce oxidative stress by causing NOS to generate reactive oxygen species [58, 59].

ADMA is liberated during catabolism of cellular proteins containing methylarginine residues, and is primarily eliminated by the enzyme dimethylarginine dimethylaminohydrolase (DDAH), an intracellular enzyme ubiquitously expressed in many cells. The disruption of DDAH activity is known to be the major cause of ADMA elevation in animal models and patients with cardiovascular risk factors [60, 61].

We have recently reported that all PPI class members in a prodrug form can directly inhibit DDAH activity. The half-maximal inhibitory concentration ( $IC_{50}$ ) of each member was determined in vitro and shown to be similar for each PPI ( $\sim 50 \mu\text{M}$ ) [62, 63]. The incubation of human endothelial cells with esomeprazole and lansoprazole resulted in increased intracellular ADMA and reduced nitrogen oxides (stable NO metabolites) levels. Isolated human saphenous veins also released less nitrogen oxides after incubation with omeprazole *ex vivo*. Furthermore, omeprazole impaired endothelium-dependent relaxation of isolated murine aorta, but did not affect endothelium-independent vasorelaxation. Lansoprazole administered to wild-type mice for 5 weeks increased circulating ADMA levels significantly, and this increase was observed as early as a week after PPI administration [63].

In addition to inhibiting DDAH, PPIs seem to directly affect NOS expression. Both phosphorylated (active) and unphosphorylated endothelial NOS proteins were down-regulated by omeprazole [63]. Altogether, these preclinical findings provide proof-of-concept that PPIs are able to impair the NO pathway in the endothelium.

PPIs may also affect an alternative pathway of NO production. It is known that inorganic nitrite, either dietary or obtained from inorganic nitrate through enzymatic conversion by commensal bacteria persisting in the oral cavity, forms nitrous acid in the acidic environment of the stomach [64]. Nitrous acid, in its turn, can spontaneously release NO [65]. It is likely that PPIs, by suppressing gastric acidity, may prevent formation of nitrous acid from inorganic nitrite, and, accordingly, NO release [66, 67]. Indeed, PPI administration to rodents blunts hypotensive effects of oral sodium nitrite [68]. Furthermore, PPI blunts the favorable effects of antioxidants on nitrite-to-NO conversion in the stomach [69] and impairs formation of gastric *S*-nitrosothiols, a circulating reservoir of NO that also drives hypotensive effects of orally administered nitrates/nitrites [70].  $H_2$ -receptor antagonists are less potent anti-secretory agents than PPIs [10] and may not have the same magnitude of effect.


It is known that endogenous NO can be recycled through oxidation into nitrate, which is actively taken up by salivary glands from the circulation, concentrated in saliva and converted into nitrite in the oral cavity (entero-salivary circulation of nitrate) [71]. Since PPIs can inhibit NO production by NOS, the decrease in circulating nitrate/nitrite levels may be expected as well, and, as a result, reduced gastric NO formation. Of note, dietary supplementation with nitrate prevented ADMA accumulation in a rodent model of chronic cardiovascular disease, likely, by protecting DDAH from oxidative stress [72]. Together, these data suggest that PPIs may impair gastric NO formation.

Another mechanism underlying the adverse cardiovascular effects of PPIs may be related to vitamin deficiencies. It was shown that PPI treatment may reduce ascorbic acid (C) and cobalamin ( $B_{12}$ ) levels [73]. As an antioxidant, ascorbic acid protects NO from degradation, and it favors conversion of nitrous acid to NO rather than *N*-nitroso compounds in the stomach [74]. Cobalamin is required for the conversion of homocysteine to methionine, and elevated homocysteine levels are known to increase ADMA levels [75]. Besides, homocysteine induces oxidative stress that also leads to NOS uncoupling, decreased NO synthesis and endothelial dysfunction [76].

Electrolyte abnormalities, such as hypomagnesemia and hypocalcemia may also mediate adverse cardiovascular effects of PPIs. Both hypomagnesemia and hypocalcemia were observed in patients taking PPIs [77, 78] and may cause cardiac arrhythmias and even congestive heart failure. Severe electrolyte abnormalities can be observed when PPIs are co-prescribed with loop diuretics. The latter are often used to manage hypertension or heart failure [79], and increase renal excretion of calcium and magnesium [80]. Indeed, changes in cardiac rhythm were recorded in 30 % of patients with PPI-induced hypomagnesemia, and the underlying cause of hypomagnesemia in such patients may be overlooked, resulting in recurrent hospitalizations [81]. Figure 1 summarizes mechanisms by which PPIs may impact cardiovascular health.

## 7 Clinical Considerations

It is important to recognize that PPIs were approved by the FDA for short-term use (weeks, rather than months or years). In the short-term, the use of PPIs probably has little adverse cardiovascular effect. Indeed, in a small randomized trial in healthy volunteers, the short-term exposure to PPIs did not have a significant effect on plasma ADMA and vasodilatory function [82]. In this small study, 11 healthy individuals and 12 patients with cardiovascular disease received lansoprazole or placebo for 4 weeks and



**Fig. 1** Model depicting the likely mechanisms underlying cardiovascular effects of proton pump inhibitors (PPIs). PPIs can reduce nitric oxide (NO) formation by inhibiting dimethylarginine dimethylaminohydrolase (DDAH) activity, expression of endothelial nitric

oxide synthase (eNOS), and reducing absorption of vitamins C and B<sub>12</sub>. In addition, PPIs can provoke electrolyte imbalance by decreasing absorption of Ca and Mg, and increase platelet aggregation interfering with clopidogrel. ADMA asymmetric dimethylarginine

then were crossed over to receive placebo. This pilot study registered a non-significant trend towards an increase in plasma ADMA after PPI administration, but endothelial function was not affected. Although this trial is somewhat reassuring with respect to short-term use of PPIs, the sample size was small and the participants were not evaluated for polymorphisms of the P-450 enzymes. The latter is a critical factor determining circulating PPI concentration and duration of exposure to the PPI [17, 83, 84]. It was shown that PPI-clopidogrel interactions become of clinical significance in poor metabolizers rather than extensive metabolizers [85]. Accordingly, poor metabolizers could have plasma PPI concentrations high enough and exposure long enough to inhibit DDAH in endothelial cells and allow ADMA to accumulate. Furthermore, the study did not assess the interaction of PPIs with other factors that are known to elevate plasma ADMA. These other factors include hyperglycemia, homocysteinemia, dyslipidemia, high levels of low-density lipoproteins, chronic inflammation and kidney dysfunction [86], and polymorphisms of DDAH [87, 88].

The preponderance of the evidence raises significant concerns regarding long-term use of PPIs, particularly in individuals with pre-existing cardiovascular disease. PPIs should be prescribed only if there are clear indications for their use. Long-term administration of PPIs is not approved

by the FDA and should be avoided. Substitution of PPIs with H<sub>2</sub>-receptor antagonists should be considered in such cases.

## 8 Conclusion

According to a majority of experimental and clinical observations, PPIs appear to have adverse cardiovascular effects. These effects may be mediated in part through an impairment in vascular homeostasis characterized by NO deficiency and should be considered when PPIs are prescribed, especially, in patients at increased cardiovascular risk. Furthermore, these observations warrant further investigations into the relationship between long-term use of PPIs and adverse cardiovascular effects. Randomized clinical trials to assess the cardiovascular safety of longer term use of PPIs are needed if these drugs are to be used over-the-counter.

### Compliance with Ethical Standards

**Funding** This study was funded in part by a Grant to Dr. Cooke from the National Institutes of Health (U01 HL100397).

**Conflict of interest** Stanford University holds patents on therapeutic modulation of the nitric oxide synthase pathway, and on

therapeutic uses of proton pump inhibitors, on which Dr. Cooke is an inventor. Dr. Sukhovshin declares that he has no conflict of interest.

## References

- Madanick RD. Proton pump inhibitor side effects and drug interactions: much ado about nothing? *Cleveland Clin J Med*. 2011;78(1):39–49. doi:10.3949/ccjm.77a.10087.
- Katz MH. Failing the acid test: benefits of proton pump inhibitors may not justify the risks for many users. *Arch Intern Med*. 2010;170(9):747–8. doi:10.1001/archinternmed.2010.64.
- Shi S, Klotz U. Proton pump inhibitors: an update of their clinical use and pharmacokinetics. *Eur J Clin Pharmacol*. 2008;64(10):935–51. doi:10.1007/s00228-008-0538-y.
- Chubineh S, Birk J. Proton pump inhibitors: the good, the bad, and the unwanted. *South Med J*. 2012;105(11):613–8. doi:10.1097/SMJ.0b013e31826efbea.
- Eid SM, Boueiz A, Paranjy S, Mativo C, Landis R, Abougergi MS. Patterns and predictors of proton pump inhibitor overuse among academic and non-academic hospitalists. *Intern Med (Tokyo, Japan)*. 2010;49(23):2561–8.
- Mazer-Amirshahi M, Mullins PM, van den Anker J, Meltzer A, Pines JM. Rising rates of proton pump inhibitor prescribing in US emergency departments. *Am J Emerg Med*. 2014;32(6):618–22. doi:10.1016/j.ajem.2014.03.019.
- Linsky A, Hermos JA, Lawler EV, Rudolph JL. Proton pump inhibitor discontinuation in long-term care. *J Am Geriatr Soc*. 2011;59(9):1658–64. doi:10.1111/j.1532-5415.2011.03545.x.
- Der G. An overview of proton pump inhibitors. *Gastroenterol Nursing Off J Soc Gastroenterol Nurses Assoc*. 2003;26(5):182–90.
- Shin JM, Munson K, Vagin O, Sachs G. The gastric HK-ATPase: structure, function, and inhibition. *Pflugers Arch*. 2009;457(3):609–22. doi:10.1007/s00424-008-0495-4.
- Huang JQ, Hunt RH. Pharmacological and pharmacodynamic essentials of H(2)-receptor antagonists and proton pump inhibitors for the practising physician. *Best Pract Res Clin Gastroenterol*. 2001;15(3):355–70. doi:10.1053/bega.2001.0184.
- Shin JM, Kim N. Pharmacokinetics and pharmacodynamics of the proton pump inhibitors. *J Neurogastroenterol Motil*. 2013;19(1):25–35. doi:10.5056/jnm.2013.19.1.25.
- Lindberg P, Nordberg P, Alminger T, Brandstrom A, Wallmark B. The mechanism of action of the gastric acid secretion inhibitor omeprazole. *J Med Chem*. 1986;29(8):1327–9.
- Shin JM, Cho YM, Sachs G. Chemistry of covalent inhibition of the gastric (H<sup>+</sup>, K<sup>+</sup>)-ATPase by proton pump inhibitors. *J Am Chem Soc*. 2004;126(25):7800–11. doi:10.1021/ja049607w.
- Marino ML, Fais S, Djavaheri-Mergny M, Villa A, Meschini S, Lozupone F, et al. Proton pump inhibition induces autophagy as a survival mechanism following oxidative stress in human melanoma cells. *Cell Death Dis*. 2010;1:e87. doi:10.1038/cddis.2010.67.
- Liu W, Baker SS, Trinidad J, Burlingame AL, Baker RD, Forte JG, et al. Inhibition of lysosomal enzyme activities by proton pump inhibitors. *J Gastroenterol*. 2013;48(12):1343–52. doi:10.1007/s00535-013-0774-5.
- Robinson M, Horn J. Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know. *Drugs*. 2003;63(24):2739–54.
- Klotz U. Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem. *Int J Clin Pharmacol Ther*. 2006;44(7):297–302.
- Furuta T, Shirai N, Sugimoto M, Nakamura A, Hishida A, Ishizaki T. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. *Drug Metab Pharmacokinet*. 2005;20(3):153–67.
- Klotz U. Pharmacokinetic considerations in the eradication of *Helicobacter pylori*. *Clin Pharmacokinet*. 2000;38(3):243–70. doi:10.2165/00003088-200038030-00004.
- Larsson H, Mattson H, Sundell G, Carlsson E. Animal pharmacodynamics of omeprazole. A survey of its pharmacological properties in vivo. *Scand J Gastroenterol Suppl*. 1985;108:23–35.
- Lamberts R, Brunner G, Solcia E. Effects of very long (up to 10 years) proton pump blockade on human gastric mucosa. *Digestion*. 2001;64(4):205–13 (48863).
- Waldum HL, Qvigstad G, Fossmark R, Kleveland PM, Sandvik AK. Rebound acid hypersecretion from a physiological, pathophysiological and clinical viewpoint. *Scand J Gastroenterol*. 2010;45(4):389–94. doi:10.3109/00365520903477348.
- Choudhry U, Boyce HW Jr, Coppola D. Proton pump inhibitor-associated gastric polyps: a retrospective analysis of their frequency, and endoscopic, histologic, and ultrastructural characteristics. *Am J Clin Pathol*. 1998;110(5):615–21.
- Hodgson N, Koniaris LG, Livingstone AS, Franceschi D. Gastric carcinoids: a temporal increase with proton pump introduction. *Surg Endosc*. 2005;19(12):1610–2. doi:10.1007/s00464-005-0232-4.
- Gray SL, LaCroix AZ, Larson J, Robbins J, Cauley JA, Manson JE, et al. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative. *Arch Intern Med*. 2010;170(9):765–71. doi:10.1001/archinternmed.2010.94.
- Targownik LE, Lix LM, Metge CJ, Prior HJ, Leung S, Leslie WD. Use of proton pump inhibitors and risk of osteoporosis-related fractures. *CMAJ Can Med Assoc J*. 2008;179(4):319–26. doi:10.1503/cmaj.071330.
- Dial MS. Proton pump inhibitor use and enteric infections. *Am J Gastroenterol*. 2009;104(Suppl 2):S10–6. doi:10.1038/ajg.2009.46.
- Sarkar M, Hennessy S, Yang YX. Proton-pump inhibitor use and the risk for community-acquired pneumonia. *Ann Intern Med*. 2008;149(6):391–8.
- Eom CS, Jeon CY, Lim JW, Cho EG, Park SM, Lee KS. Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis. *CMAJ Can Med Assoc J*. 2011;183(3):310–9. doi:10.1503/cmaj.092129.
- Wedemeyer RS, Blume H. Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update. *Drug Saf*. 2014;37(4):201–11. doi:10.1007/s40264-014-0144-0.
- Ho PM, Maddox TM, Wang L, Fihn SD, Jesse RL, Peterson ED, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. *JAMA*. 2009;301(9):937–44. doi:10.1001/jama.2009.261.
- Bhatt DL, Cryer BL, Contant CF, Cohen M, Lanos A, Schnitzer TJ, et al. Clopidogrel with or without omeprazole in coronary artery disease. *N Engl J Med*. 2010;363(20):1909–17. doi:10.1056/NEJMoa1007964.
- Juurlink DN, Gomes T, Ko DT, Szmítko PE, Austin PC, Tu JV, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. *CMAJ Can Med Assoc J*. 2009;180(7):713–8. doi:10.1503/cmaj.082001.
- Information for healthcare professionals: update to the labeling of clopidogrel bisulfate (marketed as Plavix) to alert healthcare professionals about a drug interaction with omeprazole (marketed as Prilosec and Prilosec OTC). 2009. <http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHealthcareProfessionals/ucm190787.htm>. Accessed 21 July 2015.
- Charlot M, Ahlehoff O, Norgaard ML, Jorgensen CH, Sorensen R, Abildstrom SZ, et al. Proton-pump inhibitors are associated

- with increased cardiovascular risk independent of clopidogrel use: a nationwide cohort study. *Ann Intern Med.* 2010;153(6):378–86. doi:10.7326/0003-4819-153-6-201009210-00005.
36. Schmidt M, Johansen MB, Robertson DJ, Maeng M, Kaltoft A, Jensen LO, et al. Concomitant use of clopidogrel and proton pump inhibitors is not associated with major adverse cardiovascular events following coronary stent implantation. *Aliment Pharmacol Ther.* 2012;35(1):165–74. doi:10.1111/j.1365-2036.2011.04890.x.
  37. Valkhoff VE, t Jong GW, Van Soest EM, Kuipers EJ, Sturkenboom MC. Risk of recurrent myocardial infarction with the concomitant use of clopidogrel and proton pump inhibitors. *Aliment Pharmacol Ther.* 2011;33(1):77–88. doi:10.1111/j.1365-2036.2010.04485.x.
  38. Dunn SP, Macaulay TE, Brennan DM, Campbell CL, Charnigo RJ, Smyth SS et al. Baseline proton pump inhibitor use is associated with increased cardiovascular events with and without the use of clopidogrel in the CREDO trial. *Circulation.* 2008;118(S\_815).
  39. Kwok CS, Jeevanantham V, Dawn B, Loke YK. No consistent evidence of differential cardiovascular risk amongst proton-pump inhibitors when used with clopidogrel: meta-analysis. *Int J Cardiol.* 2013;167(3):965–74. doi:10.1016/j.ijcard.2012.03.085.
  40. Melloni C, Washam JB, Jones WS, Halim SA, Hasselblad V, Mayer SB, et al. Conflicting results between randomized trials and observational studies on the impact of proton pump inhibitors on cardiovascular events when coadministered with dual antiplatelet therapy: systematic review. *Circ Cardiovasc Qual Outcomes.* 2015;8(1):47–55. doi:10.1161/circoutcomes.114.001177.
  41. Cardoso RN, Benjo AM, DiNicolantonio JJ, Garcia DC, Macedo FY, El-Hayek G, et al. Incidence of cardiovascular events and gastrointestinal bleeding in patients receiving clopidogrel with and without proton pump inhibitors: an updated meta-analysis. *Open Heart.* 2015;2(1):e000248. doi:10.1136/openhrt-2015-000248.
  42. Blackburn DF, Lamb DA, McLeod MM, Eurich DT. Increased use of acid-suppressing drugs before the occurrence of ischemic events: a potential source of confounding in recent observational studies. *Pharmacotherapy.* 2010;30(10):985–93. doi:10.1592/phco.30.10.985.
  43. Turkiewicz A, Vicente RP, Ohlsson H, Tyden P, Merlo J. Revising the link between proton-pump inhibitors and risk of acute myocardial infarction—a case-crossover analysis. *Eur J Clin Pharmacol.* 2015;71(1):125–9. doi:10.1007/s00228-014-1779-6.
  44. Juurlink DN, Dormuth CR, Huang A, Hellings C, Paterson JM, Raymond C, et al. Proton pump inhibitors and the risk of adverse cardiac events. *PLoS One.* 2013;8(12):e84890. doi:10.1371/journal.pone.0084890.
  45. Shih CJ, Chen YT, Ou SM, Li SY, Chen TJ, Wang SJ. Proton pump inhibitor use represents an independent risk factor for myocardial infarction. *Int J Cardiol.* 2014;177(1):292–7. doi:10.1016/j.ijcard.2014.09.036.
  46. Shah NH, LePendu P, Bauer-Mehren A, Ghebremariam YT, Iyer SV, Marcus J, et al. Proton pump inhibitor usage and the risk of myocardial infarction in the general population. *PLoS One.* 2015;10(6):e0124653. doi:10.1371/journal.pone.0124653.
  47. Charlot M, Grove EL, Hansen PR, Olesen JB, Ahlehoff O, Selmer C, et al. Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study. *BMJ (Clinical research ed).* 2011;342:d2690. doi:10.1136/bmj.d2690.
  48. Goodman SG, Clare R, Pieper KS, Nicolau JC, Storey RF, Cantor WJ, et al. Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial. *Circulation.* 2012;125(8):978–86. doi:10.1161/circulationaha.111.032912.
  49. Cooke JP. The pivotal role of nitric oxide for vascular health. *Can J Cardiol.* 2004;20(Suppl B):7b–15b.
  50. Tsao PS, Wang B, Buitrago R, Shyy JY, Cooke JP. Nitric oxide regulates monocyte chemotactic protein-1. *Circulation.* 1997;96(3):934–40.
  51. Sukhovshin RA, Yepuri G, Ghebremariam YT. Endothelium-derived nitric oxide as an antiatherogenic mechanism: implications for therapy. *Methodist DeBakey Cardiovasc J.* 2015;11(3):166–71. doi:10.14797/mdcj-11-3-166.
  52. Cooke JP, Singer AH, Tsao P, Zera P, Rowan RA, Billingham ME. Antiatherogenic effects of L-arginine in the hypercholesterolemic rabbit. *J Clin Invest.* 1992;90(3):1168–72. doi:10.1172/jci115937.
  53. Candipan RC, Wang BY, Buitrago R, Tsao PS, Cooke JP. Regression or progression. Dependency on vascular nitric oxide. *Arterioscler Thromb Vasc Biol.* 1996;16(1):44–50.
  54. Niebauer J, Dulak J, Chan JR, Tsao PS, Cooke JP. Gene transfer of nitric oxide synthase: effects on endothelial biology. *J Am Coll Cardiol.* 1999;34(4):1201–7.
  55. Boger RH, Bode-Boger SM, Szuba A, Tsao PS, Chan JR, Tangphao O, et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. *Circulation.* 1998;98(18):1842–7.
  56. Kielstein JT, Donnerstag F, Gasper S, Menne J, Kielstein A, Martens-Lobenhoffer J, et al. ADMA increases arterial stiffness and decreases cerebral blood flow in humans. *Stroke J Cereb Circ.* 2006;37(8):2024–9. doi:10.1161/01.str.0000231640.32543.11.
  57. Wilson AM, Shin DS, Weatherby C, Harada RK, Ng MK, Nair N, et al. Asymmetric dimethylarginine correlates with measures of disease severity, major adverse cardiovascular events and all-cause mortality in patients with peripheral arterial disease. *Vasc Med (London, England).* 2010;15(4):267–74. doi:10.1177/1358863x10364552.
  58. Cooke JP. Does ADMA cause endothelial dysfunction? *Arterioscler Thromb Vasc Biol.* 2000;20(9):2032–7.
  59. Boger RH, Cooke JP, Vallance P. ADMA: an emerging cardiovascular risk factor. *Vasc Med (London, England).* 2005;10(Suppl 1):S1–2.
  60. Cooke JP, Ghebremariam YT. DDAH says NO to ADMA. *Arterioscler Thromb Vasc Biol.* 2011;31(7):1462–4. doi:10.1161/atvbaha.111.228833.
  61. Dayoub H, Achan V, Adimoolam S, Jacobi J, Stuehlinger MC, Wang BY, et al. Dimethylarginine dimethylaminohydrolase regulates nitric oxide synthesis: genetic and physiological evidence. *Circulation.* 2003;108(24):3042–7. doi:10.1161/01.cir.0000101924.04515.2e.
  62. Ghebremariam YT, Erlanson DA, Yamada K, Cooke JP. Development of a dimethylarginine dimethylaminohydrolase (DDAH) assay for high-throughput chemical screening. *J Biomol Screen.* 2012;17(5):651–61. doi:10.1177/1087057112441521.
  63. Ghebremariam YT, LePendu P, Lee JC, Erlanson DA, Slaviero A, Shah NH, et al. Unexpected effect of proton pump inhibitors: elevation of the cardiovascular risk factor asymmetric dimethylarginine. *Circulation.* 2013;128(8):845–53. doi:10.1161/circulationaha.113.003602.
  64. Weitzberg E, Hezel M, Lundberg JO. Nitrate–nitrite–nitric oxide pathway: implications for anesthesiology and intensive care. *Anesthesiology.* 2010;113(6):1460–75. doi:10.1097/ALN.0b013e3181fcf3cc.
  65. Lundberg JO, Weitzberg E, Lundberg JM, Alving K. Intra-gastric nitric oxide production in humans: measurements in expelled air. *Gut.* 1994;35(11):1543–6.



66. Montenegro MF, Lundberg JO. Letter by Montenegro and Lundberg regarding article, "Unexpected effect of proton pump inhibitors: elevation of the cardiovascular risk factor asymmetric dimethylarginine". *Circulation*. 2014;129(13):e426. doi:10.1161/circulationaha.113.005585.
67. Pinheiro LC, Amaral JH, Tanus-Santos JE. Letter by Pinheiro et al regarding article, "Unexpected effect of proton pump inhibitors: elevation of the cardiovascular risk factor asymmetric dimethylarginine". *Circulation*. 2014;129(13):e427. doi:10.1161/circulationaha.113.005307.
68. Pinheiro LC, Montenegro MF, Amaral JH, Ferreira GC, Oliveira AM, Tanus-Santos JE. Increase in gastric pH reduces hypotensive effect of oral sodium nitrite in rats. *Free Radic Biol Med*. 2012;53(4):701–9. doi:10.1016/j.freeradbiomed.2012.06.001.
69. Amaral JH, Montenegro MF, Pinheiro LC, Ferreira GC, Barroso RP, Costa-Filho AJ, et al. TEMPOL enhances the antihypertensive effects of sodium nitrite by mechanisms facilitating nitrite-derived gastric nitric oxide formation. *Free Radic Biol Med*. 2013;65:446–55. doi:10.1016/j.freeradbiomed.2013.07.032.
70. Pinheiro LC, Amaral JH, Ferreira GC, Portella RL, Ceron CS, Montenegro MF, et al. Gastric S-nitrosothiol formation drives the antihypertensive effects of oral sodium nitrite and nitrate in a rat model of renovascular hypertension. *Free Radic Biol Med*. 2015;87:252–62. doi:10.1016/j.freeradbiomed.2015.06.038.
71. Lundberg JO, Weitzberg E, Gladwin MT. The nitrate–nitrite–nitric oxide pathway in physiology and therapeutics. *Nat Rev Drug Discov*. 2008;7(2):156–67. doi:10.1038/nrd2466.
72. Carlstrom M, Persson AE, Larsson E, Hezel M, Scheffer PG, Teerlink T, et al. Dietary nitrate attenuates oxidative stress, prevents cardiac and renal injuries, and reduces blood pressure in salt-induced hypertension. *Cardiovasc Res*. 2011;89(3):574–85. doi:10.1093/cvr/cvq366.
73. McColl KE. Effect of proton pump inhibitors on vitamins and iron. *Am J Gastroenterol*. 2009;104(Suppl 2):S5–9. doi:10.1038/ajg.2009.45.
74. Kyratopoulos SA. Ascorbic acid and the formation of N-nitroso compounds: possible role of ascorbic acid in cancer prevention. *Am J Clin Nutr*. 1987;45(5 Suppl):1344–50.
75. Stuhlinger MC, Oka RK, Graf EE, Schmolzer I, Upson BM, Kapoor O, et al. Endothelial dysfunction induced by hyperhomocyst(e)inemia: role of asymmetric dimethylarginine. *Circulation*. 2003;108(8):933–8. doi:10.1161/01.cir.0000085067.55901.89.
76. Dayal S, Lentz SR. ADMA and hyperhomocysteinemia. *Vasc Med (London, England)*. 2005;10(Suppl 1):S27–33.
77. Perazella MA. Proton pump inhibitors and hypomagnesemia: a rare but serious complication. *Kidney Int*. 2013;83(4):553–6. doi:10.1038/ki.2012.462.
78. Toh JW, Ong E, Wilson R. Hypomagnesaemia associated with long-term use of proton pump inhibitors. *Gastroenterol Rep*. 2014;. doi:10.1093/gastro/gou054.
79. Leto L, Aspromonte N, Feola M. Efficacy and safety of loop diuretic therapy in acute decompensated heart failure: a clinical review. *Heart Fail Rev*. 2014;19(2):237–46. doi:10.1007/s10741-012-9354-7.
80. Wargo KA, Banta WM. A comprehensive review of the loop diuretics: should furosemide be first line? *Ann Pharmacotherapy*. 2009;43(11):1836–47. doi:10.1345/aph.1M177.
81. Hess MW, Hoenderop JG, Bindels RJ, Drenth JP. Systematic review: hypomagnesaemia induced by proton pump inhibition. *Aliment Pharmacol Ther*. 2012;36(5):405–13. doi:10.1111/j.1365-2036.2012.05201.x.
82. Ghebremariam YT, Cooke JP, Khan F, Thakker RN, Chang P, Shah NH, et al. Proton pump inhibitors and vascular function: a prospective cross-over pilot study. *Vasc Med (London, England)*. 2015. doi:10.1177/1358863x14568444.
83. Furuta T, Shirai N, Sugimoto M, Ohashi K, Ishizaki T. Pharmacogenomics of proton pump inhibitors. *Pharmacogenomics*. 2004;5(2):181–202. doi:10.1517/phgs.5.2.181.27483.
84. Shirai N, Furuta T, Moriyama Y, Okochi H, Kobayashi K, Takashima M, et al. Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH. *Aliment Pharmacol Ther*. 2001;15(12):1929–37.
85. Depta JP, Lenzini PA, Lanfear DE, Wang TY, Spertus JA, Bach RG, et al. Clinical outcomes associated with proton pump inhibitor use among clopidogrel-treated patients within CYP2C19 genotype groups following acute myocardial infarction. *Pharmacogenomics J*. 2015;15(1):20–5. doi:10.1038/tpj.2014.28.
86. Palm F, Onozato ML, Luo Z, Wilcox CS. Dimethylarginine dimethylaminohydrolase (DDAH): expression, regulation, and function in the cardiovascular and renal systems. *Am J Physiol Heart Circ Physiol*. 2007;293(6):H3227–45. doi:10.1152/ajpheart.00998.2007.
87. Valkonen VP, Tuomainen TP, Laaksonen R. DDAH gene and cardiovascular risk. *Vasc Med (London, England)*. 2005;10(Suppl 1):S45–8.
88. Ryan R, Thornton J, Duggan E, McGovern E, O'Dwyer MJ, Ryan AW, et al. Gene polymorphism and requirement for vasopressor infusion after cardiac surgery. *Ann Thorac Surg*. 2006;82(3):895–901. doi:10.1016/j.athoracsur.2006.04.029.